cmAngio® vs Zio XT ECG Monitoring System
AI Verdict
Choose cmAngio® if…
Choose cmAngio if your primary goal is to leverage existing mammography data for an early, non-invasive assessment of a woman's cardiovascular risk. This tool is ideal for integrating cardiovascular insights into routine breast cancer screening programs, allowing for proactive identification of patients who may benefit from further cardiac evaluation without additional procedures or radiation.
View cmAngio® →Choose Zio XT ECG Monitoring System if…
Choose the Zio XT ECG Monitoring System if you need to continuously monitor a patient's cardiac rhythm for an extended period (up to 14 days) to detect and diagnose intermittent arrhythmias. This wearable solution is best suited for patients experiencing transient symptoms like palpitations or syncope, or for post-treatment monitoring, offering high compliance and accurate, AI-powered analysis without the need for external wires.
View Zio XT ECG Monitoring System →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | cmAngio® | Zio XT ECG Monitoring System |
|---|---|---|
| Pricing | Paid, out-of-pocket | Contact for pricing |
| Deployment | Cloud-based, integrates with any DICOM-compliant viewer | Cloud-based (AWS EC2 platform), no on-premise hardware required. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Zio XT ECG Monitoring SystemTool B emphasizes patient comfort and ease of use for continuous monitoring with its wearable, leadless design, water resistance, and high patient compliance (up to 99%). While Tool A focuses on seamless integration into existing radiology workflows, Tool B's patient-centric design offers a broader impact on usability for the end-user.
Clinical Value
TieBoth tools offer significant and distinct clinical value. Tool A innovatively leverages existing mammogram data for early cardiovascular risk assessment by detecting Breast Arterial Calcifications (BAC) without additional procedures. Tool B provides extended, continuous cardiac monitoring for accurate arrhythmia detection and diagnosis, addressing a direct and critical diagnostic need.
Pricing & Value
Zio XT ECG Monitoring SystemTool B offers greater transparency in its pricing, providing specific per-patient costs for the UK (u00a3310) and proposed US Medicare rates (approximately $229-$260.35). This allows for clearer financial planning. Tool A's pricing is not publicly available, requiring direct contact with the vendor, which is less transparent.
Enterprise Readiness
Zio XT ECG Monitoring SystemBoth tools are cloud-based, FDA-cleared, and HIPAA-compliant. However, Tool B explicitly states it 'has_baa: yes', indicating a readily available Business Associate Agreement. Tool A requires contacting the vendor for BAA details, which can introduce delays in enterprise adoption.
Innovation
cmAngio®Tool A demonstrates strong innovation by repurposing existing mammography data through AI to detect Breast Arterial Calcifications (BAC) for cardiovascular risk assessment, transforming a routine screening into a dual-purpose diagnostic tool. This novel application of AI to extract new insights from established imaging is particularly impactful. Tool B also innovates in wearable cardiac monitoring, but Tool A's approach feels more disruptive in its use of existing data.
Support & Docs
Zio XT ECG Monitoring SystemTool B provides clear evidence of comprehensive support, including 'Patient Support and FAQs', 'Customer Care' phone numbers, 'Patient Instructions & Button Press Log', and 'Clinical Reference Manual'. Tool A only mentions an 'Operator's Manual' without publicly available details on broader support channels.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | cmAngio® | Zio XT ECG Monitoring System |
|---|---|---|
| Name | cmAngiou00ae | Zio XT ECG Monitoring System |
| Company | CureMetrix | iRhythm Technologies |
| Description | FDA-cleared AI software for detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment. | Wearable, single-lead ECG biosensor for up to 14 days of continuous cardiac monitoring, utilizing FDA-cleared AI and expert review for accurate arrhythmia detection and diagnosis. |
| Primary Function | AI-based detection of Breast Arterial Calcifications (BAC) | Continuous ambulatory cardiac monitoring for up to 14 days |
| Key Feature 1 | AI-based detection of Breast Arterial Calcifications (BAC) | Wearable single-lead ECG biosensor (Zio biosensor) |
| Key Feature 2 | Processes both Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams | Continuous ambulatory cardiac monitoring for up to 14 days |
Videos
Demos, reviews, and walkthroughs featuring cmAngio® and Zio XT ECG Monitoring System.
Frequently Asked Questions
More Comparisons
More matchups featuring cmAngio® or Zio XT ECG Monitoring System
Backers
Who funded each tool's parent company.